Authored By: Sarah
11 Jul 2024

 Primary Biliary Cholangitis Therapeutics Market to grow by USD 346.85 million between 2024-2028

According to a research report “ Primary Biliary Cholangitis Therapeutics Market” by Type (Primary drug, Secondary drug) Distribution Channel (Drug stores and retail pharmacies, Hospital pharmacies, Online pharmacies) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 346.85 million at a CAGR of  8.75% during the forecast period. The COVID-19 pandemic in 2020 catalyzed the telehealth industry's growth, revolutionizing healthcare delivery for Primary Biliary Cholangitis (PBC) patients. Telehealth facilitates remote consultations, diagnostics, treatments, and monitoring, enhancing patient access to specialized care. PBC patients can now virtually consult specialists, reducing travel challenges. Telehealth empowers healthcare providers to diagnose PBC remotely via video consultations, patient histories, and shared medical data. By preventing non-essential in-person visits and focusing resources on critical cases, telehealth and remote monitoring alleviate healthcare facility burdens. Additionally, remote monitoring technologies enable care delivery at patients' homes..

Browse market data tables, figures, and in-depth TOC on “Primary Biliary Cholangitis Therapeutics Market” by Type (Primary drug, Secondary drug) Distribution Channel (Drug stores and retail pharmacies, Hospital pharmacies, Online pharmacies) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028.

 View detailed Table of Content- Click here

By Type, the Primary drug segment is projected to dominate the market size in 2024.

In the Primary Biliary Cholangitis (PBC) Therapeutics Market, drug stores and retail pharmacies held a significant market share in 2023. This dominance can be attributed to the high sales volume of PBC drugs in these channels. The geriatric demographic, more susceptible to various health conditions, fuels this trend. Factors driving growth in this segment include an aging population, heightened awareness and screening initiatives for PBC, and the preference for outpatient care and follow-up treatments outside of hospitals.

By Distribution Channel, Drug stores and retail pharmacies  segment is expected to hold the largest market size for the year 2024.

In the Primary Biliary Cholangitis (PBC) Therapeutics Market, the primary drug segment is poised for significant expansion. Factors such as the high adoption rate of primary drugs for PBC treatment, their proven efficacy, and the increasing patient population are key growth drivers. Furthermore, the pipeline boasts numerous primary drugs, enhancing market potential. Consequently, the primary drug segment is projected to dominate the global PBC Therapeutics Market throughout the forecast period.

North America is forecasted to hold the largest market size by region in 2024.

In the North American market, primary biliary cholangitis (PBC) therapeutics hold a significant market share in 2023. This regional dominance is driven by several factors, including an increase in clinical trials, advanced healthcare infrastructure, and substantial healthcare expenditures from government organizations. The growing awareness of PBC and the necessity to treat it in its early stages further fuel the expansion of the PBC therapeutics market in North America and globally.

The Primary Biliary Cholangitis Therapeutics Market t growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Abbott Laboratories
  • AbbVie Inc.
  • Alkem Laboratories Ltd.
  • Eli Lilly and Co.
  • GENFIT SA
  • Glenmark Pharmaceuticals Ltd.
  • ICE S.p.a.
  • Intercept Pharmaceuticals Inc.
  • Ipsen Pharma
  • Leeford Healthcare Ltd.
  • NGM Biopharmaceuticals Inc.
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Ltd.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Primary Biliary Cholangitis (PBC) therapeutics market has witnessed significant advancements in the treatment of this autoimmune liver disease. The robust healthcare infrastructure and pharmaceutical supply chain have facilitated the diagnosis of PBC, despite the lack of awareness surrounding this condition. PBC is characterized by liver damage, bile flow disruption, and small bile ducts inflammation. Immune system dysfunction and environmental triggers are believed to contribute to the disease's development. Combination therapies, such as Obeticholic acid and Ursodeoxycholic acid, have emerged as promising treatments for PBC. These therapies target the underlying causes of the disease, including immune system dysregulation and bile duct damage. Clinical trials are ongoing to further evaluate their efficacy and safety. Genetic predispositions also play a role in PBC development. Understanding these predispositions can lead to the development of targeted therapies and improved patient outcomes. The market for PBC therapeutics is expected to grow as new treatments and diagnostic tools become available, offering hope to the millions affected by this debilitating condition. Keywords: Advancements, Liver failure, Cirrhosis, Immune system, Liver damage, Infections, Environmental triggers, Liver, Bile flow, Small bile ducts, Autoimmune liver disease, Primary Biliary Cholangitis, Autoimmune diseases, Robust healthcare infrastructure, Pharmaceutical supply chain, Diagnosis, Lack of awareness, Combination therapies, Clinical trials, Genetic predispositions, Obeticholic acid, Ursodeoxycholic acid.

Market Research Overview

The Primary Biliary Cholangitis (PBC) Therapeutics Market encompasses a range of treatment options for autoimmune biliary diseases, including symptomatic therapies and bile-acid modulators. The prevalence of PBC is significant, particularly among those with autoimmune diseases and genetic predispositions. Limited advancements in treatment have resulted in a reliance on Ursodeoxycholic acid (UDCA) as a primary therapy. However, recent developments, such as the use of Obeticholic acid, offer promising alternatives. Despite these advancements, liver failure and cirrhosis remain potential complications for PBC patients. The immune system plays a crucial role in the underlying mechanisms of liver damage, making robust healthcare infrastructure and a reliable pharmaceutical supply chain essential. Diagnosis of PBC can be challenging due to a lack of awareness and the complex nature of the disease. Online and hospital pharmacies are crucial in providing access to effective therapies, including combinations of UDCA and other drugs. Harmful substances, infections, and environmental triggers can exacerbate PBC, highlighting the importance of healthcare investments in advanced facilities and clinical trials. The pharmaceutical manufacturing sector continues to research and develop new treatments, offering hope for those affected by this rare liver condition.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio